

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Duality Biotherapeutics, Inc.

映恩生物

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9606)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 20, 2025

References are made to the notice of annual general meeting (the “**Notice**”) and the circular (the “**Circular**”) of Duality Biotherapeutics, Inc. (the “**Company**”) both dated May 29, 2025. Unless otherwise indicated, capitalized terms used herein have the same meanings as those defined in the Circular.

The Board is pleased to announce that all the proposed resolutions as set out in the Notice were duly passed by the Shareholders by way of poll at the AGM.

The poll results in respect of the ordinary resolutions proposed at the AGM were as follows:

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company as of and for the year ended December 31, 2024 as disclosed in the prospectus of the Company dated April 7, 2025.	60,798,541 (100.000000%)	0 (0.000000%)
2.	(a) To re-elect the following retiring directors of the Company (the “ Director(s) ”):		
	(i) Dr. ZHU Zhongyuan as an executive Director.	59,775,893 (98.317973%)	1,022,648 (1.682027%)
	(ii) Mr. ZHANG Shaoren as an executive Director.	60,798,541 (100.000000%)	0 (0.000000%)
	(iii) Dr. YU Tao as a non-executive Director.	60,465,193 (99.451717%)	333,348 (0.548283%)
	(b) To authorise the board of the Directors to fix the remuneration of the Directors.	60,798,541 (100.000000%)	0 (0.000000%)

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
3.	To re-appoint PricewaterhouseCoopers as auditors of the Company and authorise the Directors to fix their remuneration.	60,158,041 (98.946521%)	640,500 (1.053479%)
4.	To grant a general mandate to the Directors to repurchase shares of the Company not exceeding 10% of the total number of shares of the Company in issue (excluding treasury shares) as at the date of passing of this resolution.	60,798,541 (100.000000%)	0 (0.000000%)
5.	To grant a general mandate to the Directors to allot, issue and deal with shares of the Company and/or to sell or transfer treasury shares of the Company involving a maximum of 20% of the total number of shares of the Company in issue (excluding treasury shares) as at the date of passing of this resolution.	56,993,631 (93.741774%)	3,804,910 (6.258226%)
6.	To extend the general mandate granted under resolution no. 5 by adding the shares of the Company repurchased pursuant to the general mandate granted by resolution no. 4.	57,556,731 (94.667948%)	3,241,810 (5.332052%)

As more than 50% of the votes held by Shareholders present at the AGM in person or by proxy were cast in favour of the resolutions no. 1 to no. 6, the resolutions no. 1 to no. 6 proposed at the AGM were duly passed as ordinary resolutions of the Company.

As at the date of the AGM, the total number of issued Shares of the Company was 88,036,264 Shares which represented the total number of Shares entitling the Shareholders to attend and vote for or against all the resolutions proposed at the AGM. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Listing Rules. No Shareholder was required under the Listing Rules to abstain from voting on the proposed resolutions at the AGM. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the AGM.

The Hong Kong share registrar of the Company, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the purpose of vote-taking at the AGM.

All Directors attended the AGM in person or by electronic means.

By order of the Board
Duality Biotherapeutics, Inc.
Dr. ZHU Zhongyuan
*Chairman of the Board, Executive
Director and Chief Executive
Officer*

Hong Kong, June 20, 2025

As at the date of this announcement, the board of directors of the Company comprises (i) Dr. ZHU Zhongyuan, Mr. ZHANG Shaoren and Ms. SI Wen as executive directors; (ii) Mr. CAI Zhiyang and Dr. YU Tao as non-executive directors; and (iii) Mr. XIE Dong, Mr. GAO Fengyong and Ms. CHUAI Shuyin as independent non-executive directors.